Logo

bladder cancer

Diatech, Janssen Partner to Develop Molecular Diagnostics for Bladder Cancer

The bladder cancer test in development will profile genetic alterations in bladder cancer in three hours using real-time PCR.

New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy

The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.

Convergent Genomics Building Data on Urine-Based Assay to Diagnose, Monitor Urothelial Carcinoma
Premium

The Oregon Health and Science University spinout also recently presented data suggesting the test could help predict future urothelial carcinoma. 

GeneCentric Begins Study to Validate RNA Gene Signature Test in Bladder Cancer

GeneCentric investigators will assess the ability of the FGFR predictive response signature to identify bladder cancer patients who may benefit from targeted therapy.

Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test

Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.

May 4, 2023

Nucleix Bladder EpiCheck Cancer Liquid Biopsy Test Gets FDA 510(k) Clearance

Apr 28, 2023

Pacific Edge Ramps up Clinical Utility Studies, Commercial Efforts Behind Bladder Cancer Test
Premium

Mar 24, 2023

British Liquid Biopsy Firm Nonacus Launches Urine-Based Bladder Cancer Assay
Premium

Feb 15, 2023

NeoGenomics Eyes Bladder Cancer as Future Indication for Radar MRD Test
Premium

Nov 30, 2022

Bladder Cancer Genomic Landscape Study Aims to Engender New Biomarker-Guided Therapies
Premium

Nov 2, 2022

Diagnostics Developer Early is Good Raises $4M in Seed Funding

Jul 11, 2022

Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways

Jun 23, 2022

Nucleix Expands EU Label Indication for Bladder Cancer Urine Test

May 23, 2022

Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership

Aug 31, 2021

Cell-Free DNA Can Help Predict Pathological Complete Response, Gauge Minimal Residual Disease

Jul 1, 2021

European Consortium Nets €1M for Test to Predict Bladder Cancer Immunotherapy Response

Jul 1, 2021

University of Birmingham, Nonacus to Develop Urine Cancer Liquid Biopsy Assay

Jun 18, 2021

Natera Aims to Lead Market in Solid Tumor Adjuvant CDx, Supported by New Liquid Biopsy Data
Premium

Jun 4, 2021

Veracyte Bladder Cancer Test Receives Medicare Coverage

Apr 16, 2021

OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence
Premium

Apr 12, 2021

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

Apr 9, 2021

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Apr 8, 2021

Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx
Premium

Mar 18, 2021

Oncocyte Details New Expansions Plans With Growing Portfolio of Acquired Tests
Premium

Mar 15, 2021

OncoDiag Raises $3M to Market Test for Early Detection of Recurrent Bladder Cancer

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.